GSK and iTeos ends development of anti-TIGIT drug after trial failure

GSK and iTeos have discontinued all development of their anti-TIGIT antibody belrestotug following disappointing Phase II trial results. Despite initially positive data at ESMO 2024, interim analyses from the GALAXIES Lung-201 and GALAXIES H&N-202 studies failed to meet key efficacy endpoints, particularly progression-free survival (PFS). Both trials tested belrestotug combined with PD-1 inhibitor Jemperli in advanced non-small-cell lung cancer (NSCLC) and PD-L1-positive head and neck cancer, respectively.

The companies announced ending all belrestotug programs, including enrollment in the ongoing Phase III GALAXIES Lung-301 trial. GSK and iTeos join other major pharma firms like MSD, Roche, and BeiGene in halting anti-TIGIT programs due to similar setbacks. However, some anti-TIGIT candidates, such as Gilead’s domvanalimab and AstraZeneca’s bispecific rilvegostomig, continue clinical development.

19-05-2025